These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 22551036)

  • 41. Subjective response to alcohol among alcohol-dependent individuals: effects of the μ-opioid receptor (OPRM1) gene and alcoholism severity.
    Ray LA; Bujarski S; MacKillop J; Courtney KE; Monti PM; Miotto K
    Alcohol Clin Exp Res; 2013 Jan; 37 Suppl 1(Suppl 1):E116-24. PubMed ID: 23240711
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study.
    Bujarski S; MacKillop J; Ray LA
    Exp Clin Psychopharmacol; 2012 Jun; 20(3):181-90. PubMed ID: 22429255
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential neural response to alcohol priming and alcohol taste cues is associated with DRD4 VNTR and OPRM1 genotypes.
    Filbey FM; Ray L; Smolen A; Claus ED; Audette A; Hutchison KE
    Alcohol Clin Exp Res; 2008 Jul; 32(7):1113-23. PubMed ID: 18540916
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys.
    Vallender EJ; Rüedi-Bettschen D; Miller GM; Platt DM
    Drug Alcohol Depend; 2010 Jun; 109(1-3):252-6. PubMed ID: 20153935
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus.
    Barr CS; Chen SA; Schwandt ML; Lindell SG; Sun H; Suomi SJ; Heilig M
    Biol Psychiatry; 2010 Jan; 67(1):78-80. PubMed ID: 19748082
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype.
    Setiawan E; Pihl RO; Cox SM; Gianoulakis C; Palmour RM; Benkelfat C; Leyton M
    Alcohol Clin Exp Res; 2011 Jun; 35(6):1134-41. PubMed ID: 21410481
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis.
    Chamorro AJ; Marcos M; Mirón-Canelo JA; Pastor I; González-Sarmiento R; Laso FJ
    Addict Biol; 2012 May; 17(3):505-12. PubMed ID: 22515274
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial.
    Krishnan-Sarin S; O'Malley SS; Franco N; Cavallo DA; Tetrault JM; Shi J; Gueorguieva R; Pittman B; Krystal JH
    Neuropsychopharmacology; 2020 Jan; 45(2):319-326. PubMed ID: 31590179
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.
    O'Malley SS; Krishnan-Sarin S; Farren C; Sinha R; Kreek MJ
    Psychopharmacology (Berl); 2002 Feb; 160(1):19-29. PubMed ID: 11862370
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Case-control, family based and screening for DNA sequence variation in the dopamine transporter gene polymorphism DAT 1 in alcohol dependence].
    Grzywacz A; Samochowiec J
    Psychiatr Pol; 2008; 42(3):443-52. PubMed ID: 19899571
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence.
    Ait-Daoud N; Johnson BA; Prihoda TJ; Hargita ID
    Psychopharmacology (Berl); 2001 Feb; 154(1):23-7. PubMed ID: 11292002
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.
    Setiawan E; Pihl RO; Benkelfat C; Leyton M
    Pharmacogenomics; 2012 Jul; 13(10):1161-72. PubMed ID: 22909206
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A pharmacogenetic determinant of mu-opioid receptor antagonist effects on alcohol reward and consumption: evidence from humanized mice.
    Bilbao A; Robinson JE; Heilig M; Malanga CJ; Spanagel R; Sommer WH; Thorsell A
    Biol Psychiatry; 2015 May; 77(10):850-8. PubMed ID: 25442002
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers.
    van den Wildenberg E; Wiers RW; Dessers J; Janssen RG; Lambrichs EH; Smeets HJ; van Breukelen GJ
    Alcohol Clin Exp Res; 2007 Jan; 31(1):1-10. PubMed ID: 17207095
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-time assessment of alcohol craving and naltrexone treatment responsiveness in a randomized clinical trial.
    Miranda R; Treloar Padovano H; Gray JC; Wemm SE; Blanchard A
    Addict Behav; 2018 Aug; 83():72-78. PubMed ID: 29395188
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers.
    Arias AJ; Armeli S; Gelernter J; Covault J; Kallio A; Karhuvaara S; Koivisto T; Mäkelä R; Kranzler HR
    Alcohol Clin Exp Res; 2008 Jul; 32(7):1159-66. PubMed ID: 18537939
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers.
    Drobes DJ; Anton RF; Thomas SE; Voronin K
    Alcohol Clin Exp Res; 2004 Sep; 28(9):1362-70. PubMed ID: 15365307
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
    Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
    J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving.
    de Laat B; Goldberg A; Shi J; Tetrault JM; Nabulsi N; Zheng MQ; Najafzadeh S; Gao H; Kapinos M; Ropchan J; O'Malley SS; Huang Y; Morris ED; Krishnan-Sarin S
    Biol Psychiatry; 2019 Dec; 86(11):864-871. PubMed ID: 31399255
    [TBL] [Abstract][Full Text] [Related]  

  • 60. OPRM1 A118G and serum β-endorphin interact with sex and digit ratio (2D:4D) to influence risk and course of alcohol dependence.
    Gegenhuber B; Weinland C; Kornhuber J; Mühle C; Lenz B
    Eur Neuropsychopharmacol; 2018 Dec; 28(12):1418-1428. PubMed ID: 30322771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.